Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISMO vs NITRO IV
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.
Nitroglycerin is a vasodilator that primarily acts by relaxing vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase to increase c GMP, leading to venodilation and, at higher doses, arterial dilation. This reduces preload and afterload, decreasing myocardial oxygen demand.
Prevention of angina pectoris due to coronary artery disease,Off-label: Treatment of acute angina (immediate-release forms)
Acute angina pectoris,Prophylaxis of angina (before exercise or stress),Congestive heart failure (acute),Controlled hypotension during surgery,Hypertensive emergencies (off-label),Pulmonary edema (off-label)
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
Initial infusion rate 5 mcg/min via continuous IV infusion, titrate by 5 mcg/min every 3-5 minutes until response; usual maintenance dose 10-20 mcg/min; maximum 200 mcg/min.
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
1-4 minutes (rapidly cleared from blood); terminal half-life ~2-3 minutes due to rapid biotransformation in RBCs and vascular tissue.
Primarily metabolized in the liver by denitration; minor metabolism via glucuronidation. Metabolites are inactive.
Nitroglycerin is extensively metabolized in the liver by glutathione S-transferases and, to a lesser extent, by arterial walls. It undergoes denitration to form 1,2- and 1,3-glyceryl dinitrate, which have weaker vasodilatory activity.
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
Renal (minimal, <1% unchanged) and hepatic metabolism; metabolites excreted renally.
Approximately 30% bound to plasma proteins, primarily albumin.
60% bound to albumin.
Vd is 0.6-0.9 L/kg, indicating distribution into total body water. Higher Vd may be observed in patients with heart failure.
3-4 L/kg (high, due to extensive tissue uptake, especially vascular smooth muscle).
Oral: 90-100% (sustained-release formulations). Sublingual: high but variable; generally effective due to extensive absorption.
IV: 100% (not administered via other routes due to extensive first-pass metabolism).
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, consider reducing dose to 10 mg twice daily due to potential accumulation of active metabolite.
No dose adjustment required for GFR ≥30 m L/min; for GFR <30 m L/min, consider dose reduction due to risk of methemoglobinemia and cyanide toxicity, monitor closely.
No dose adjustment in Child-Pugh A or B. For Child-Pugh C, reduce dose to 10 mg twice daily and monitor for hypotension.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use or use with extreme caution, reduce dose by 75%.
Safety and efficacy not established; no standard dosing recommendations.
0.25-0.5 mcg/kg/min IV continuous infusion, titrate by 0.5-1 mcg/kg/min every 3-5 minutes; maximum 5 mcg/kg/min for children.
Start at 10 mg twice daily with gradual titration based on tolerance and renal function. Monitor for hypotension and dizziness.
Initiate at lower end of dosing range (5 mcg/min) due to increased sensitivity; titrate slowly with careful hemodynamic monitoring.
Do not use with phosphodiesterase-5 (PDE-5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Nitroglycerin is contraindicated in patients with severe anemia, increased intracranial pressure, or those using phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension.
Hypotension and reflex tachycardia may occur,Caution in patients with volume depletion or hypotension,May cause headaches; tolerance may develop with prolonged use,Abrupt withdrawal may increase angina frequency
Hypotension and reflex tachycardia may occur; monitor blood pressure,May exacerbate angina from abrupt discontinuation (tolerance and rebound),Caution in patients with hypovolemia, right ventricular infarction, or hypertrophic cardiomyopathy,Avoid in patients with constrictive pericarditis or pericardial tamponade,May cause methemoglobinemia, especially with high doses or prolonged use
Concurrent use of PDE-5 inhibitors,Severe anemia,Closed-angle glaucoma,Hypersensitivity to isosorbide mononitrate or nitrates,Acute myocardial infarction with low filling pressures
Allergy to nitroglycerin or nitrates,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Concomitant use of phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil),Hypotension (systolic BP < 90 mm Hg),Right ventricular infarction,Constrictive pericarditis,Pericardial tamponade
Alcohol may enhance hypotension risk. Avoid high-fat meals if extended-release formulation, as they may affect absorption. No other significant food interactions.
No specific food restrictions. Avoid alcohol as it may enhance vasodilation and hypotension.
ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate human studies exist. Use only if potential benefit justifies risk. First trimester: Theoretical risk of hemodynamic effects; avoid unless necessary. Second/third trimester: May cause fetal hypoxia due to maternal hypotension; monitor fetal heart rate. Peripartum: May exacerbate uterine relaxation and postpartum hemorrhage if used near delivery.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal harm at high doses. Second/third trimester: Potential risk of fetal bradycardia and hypotension; use only if clearly needed. Avoid near term due to risk of uterine relaxation and hemorrhage.
Excretion into human milk is unknown. Due to risk of infant methemoglobinemia and hypotension, caution is advised. M/P ratio: Not available. American Academy of Pediatrics considers nitrate derivatives compatible with breastfeeding, but monitor infant for cyanosis and lethargy.
Unknown excretion in human milk. M/P ratio not established. Short half-life suggests minimal exposure; however, use with caution and consider risk of infant hypotension.
No specific dose adjustments for ISMO in pregnancy are established due to lack of pharmacokinetic studies. However, pregnancy-induced hemodynamic changes (increased plasma volume, cardiac output) may reduce efficacy; consider dose titration based on clinical response. Avoid doses >60 mg/day to minimize hypotensive risk. Use immediate-release formulations for flexible dosing if needed.
No standard dose adjustment in pregnancy. Consider higher initial doses due to increased volume of distribution and clearance, but titrate to effect due to potential for heightened sensitivity.
ISMO (isosorbide mononitrate) is a nitrate used for angina prophylaxis, not for acute attacks. Tolerance develops with sustained use; maintain a 10-12 hour nitrate-free interval to prevent tolerance. Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of profound hypotension. Contraindicated in severe anemia, increased intracranial pressure, or hypertrophic obstructive cardiomyopathy. Discontinue if blurred vision or dry mouth occurs.
Use non-PVC infusion sets to minimize drug adsorption. Monitor for hypotension, especially with concurrent PDE-5 inhibitor use. Tolerance can develop with prolonged infusion; use lowest effective dose. Do not abruptly discontinue after prolonged use to avoid rebound ischemia. Avoid in patients with right ventricular infarction or severe aortic stenosis.
Take as prescribed to prevent angina; do not use for acute attacks.,May cause headache, dizziness, or hypotension; rise slowly from sitting.,Avoid taking erectile dysfunction drugs (e.g., sildenafil, tadalafil) as severe blood pressure drop can occur.,Do not stop abruptly to avoid rebound angina.,Store in original container away from light and moisture.
Report any severe headaches, dizziness, or fainting during infusion.,Avoid taking erectile dysfunction medications like sildenafil or tadalafil while on this treatment.,Notify your healthcare provider if you have a history of low blood pressure or recent heart attack.,The medication will be given by a healthcare professional and vital signs will be monitored closely.,Do not stop the infusion suddenly without medical advice.
"Bosentan, a dual endothelin receptor antagonist and an inducer of CYP3A4 and CYP2C9, reduces systemic exposure to vismodegib, a Hedgehog pathway inhibitor primarily metabolized by CYP3A4. This interaction leads to decreased serum concentrations of vismodegib, potentially diminishing its antitumor efficacy in patients with advanced basal cell carcinoma. Concomitant use may require vismodegib dose adjustment or alternative therapies to avoid therapeutic failure."
"Vismodegib inhibits CYP3A4, which is the primary enzyme responsible for metabolizing nilotinib. Concomitant administration may lead to increased nilotinib plasma concentrations, elevating the risk of QT interval prolongation, torsades de pointes, hepatotoxicity, and myelosuppression. Clinical vigilance is warranted due to the narrow therapeutic index of nilotinib."
"Vismodegib, a hedgehog pathway inhibitor, is a moderate inhibitor of CYP2C9, the primary enzyme responsible for metabolizing tolbutamide. Concomitant use can significantly decrease tolbutamide clearance, leading to elevated plasma concentrations and prolonged hypoglycemic effects. This increases the risk of severe hypoglycemia, especially in diabetic patients, and may require dose adjustment of tolbutamide."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISMO vs NITRO IV, answered by our medical review team.
ISMO is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing c GMP levels, leading to smooth muscle relaxation and vasodilation.. NITRO IV is a Nitrate Vasodilator that works by Nitroglycerin is a vasodilator that primarily acts by relaxing vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase to increase c GMP, leading to venodilation and, at higher doses, arterial dilation. This reduces preload and afterload, decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISMO and NITRO IV depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISMO is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.. The standard adult dose of NITRO IV is: Initial infusion rate 5 mcg/min via continuous IV infusion, titrate by 5 mcg/min every 3-5 minutes until response; usual maintenance dose 10-20 mcg/min; maximum 200 mcg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISMO and NITRO IV in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISMO is classified as Category C. ISMO (isosorbide mononitrate) is categorized as FDA Pregnancy Category C. In animal studies, reduced fetal survival and growth retardation were observed at high doses. No adequate . NITRO IV is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal harm at high doses. Second/third trimester: Potential risk of fetal bradycardia and hypoten. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.